Literature DB >> 21098404

Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy.

C i Dali1, L G Hanson, N W Barton, J Fogh, N Nair, A M Lund.   

Abstract

BACKGROUND: Late infantile metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder that causes severe demyelination of the nervous system. The neuronal metabolite N-acetylaspartate (NAA) serves as a source of acetyl groups for myelin lipid synthesis in oligodendrocytes and is known as a marker for neuronal and axonal loss. NAA and other metabolite levels measured by proton magnetic resonance spectroscopy (MRS) correlate with performance of the brain in normal children. There is a need for sensitive measures of disease progression in patients with MLD to enable development of future treatments.
METHODS: A cross-section of 13 children with late infantile MLD were examined by proton MRS. Signals from NAA, total choline, and total creatine in the deep white matter were measured and correlated with the results of cognitive and motor function tests.
RESULTS: The NAA signal decreased as the disease process advanced. Motor function, measured by the Gross Motor Function Measure-88, varied from 13 (only head movement in the supine position) to 180 (able to walk) across the study cohort, demonstrating a wide range in functional status. Similarly, varied decreases were observed in cognitive function. We report strong positive correlations between standardized measures of motor and cognitive function and NAA levels in the deep white matter.
CONCLUSIONS: We suggest that NAA levels could serve as a sensitive biomarker in children with MLD. Proton MRS may provide a valuable tool for measuring the effects of treatment interventions in this disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098404     DOI: 10.1212/WNL.0b013e3181feb217

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution.

Authors:  A Martin; C Sevin; C Lazarus; C Bellesme; P Aubourg; C Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

3.  Cerebral gray and white matter changes and clinical course in metachromatic leukodystrophy.

Authors:  Samuel Groeschel; Christine í Dali; Philipp Clas; Judith Böhringer; Morten Duno; Christian Krarup; Christiane Kehrer; Marko Wilke; Ingeborg Krägeloh-Mann
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

4.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 6.  Clinical proton MR spectroscopy in central nervous system disorders.

Authors:  Gülin Oz; Jeffry R Alger; Peter B Barker; Robert Bartha; Alberto Bizzi; Chris Boesch; Patrick J Bolan; Kevin M Brindle; Cristina Cudalbu; Alp Dinçer; Ulrike Dydak; Uzay E Emir; Jens Frahm; Ramón Gilberto González; Stephan Gruber; Rolf Gruetter; Rakesh K Gupta; Arend Heerschap; Anke Henning; Hoby P Hetherington; Franklyn A Howe; Petra S Hüppi; Ralph E Hurd; Kantarci Kantarci; Dennis W J Klomp; Roland Kreis; Marijn J Kruiskamp; Martin O Leach; Alexander P Lin; Peter R Luijten; Malgorzata Marjańska; Andrew A Maudsley; Dieter J Meyerhoff; Carolyn E Mountford; Sarah J Nelson; M Necmettin Pamir; Jullie W Pan; Andrew C Peet; Harish Poptani; Stefan Posse; Petra J W Pouwels; Eva-Maria Ratai; Brian D Ross; Tom W Scheenen; Christian Schuster; Ian C P Smith; Brian J Soher; Ivan Tkáč; Daniel B Vigneron; Risto A Kauppinen
Journal:  Radiology       Date:  2014-03       Impact factor: 11.105

7.  Vitamin k antagonist warfarin for palliative treatment of metachromatic leukodystrophy, a compassionate study of four subjects.

Authors:  Mitra Assadi; Dah-Jyuu Wang; Kelly Anderson; Melissa Carran; Larissa Bilaniuk; Paola Leone
Journal:  J Cent Nerv Syst Dis       Date:  2012-04-26

8.  Sulfatide levels correlate with severity of neuropathy in metachromatic leukodystrophy.

Authors:  Christine Í Dali; Norman W Barton; Mohamed H Farah; Mihai Moldovan; Jan-Eric Månsson; Nitin Nair; Morten Dunø; Lotte Risom; Hongmei Cao; Luying Pan; Marcia Sellos-Moura; Andrea M Corse; Christian Krarup
Journal:  Ann Clin Transl Neurol       Date:  2015-03-27       Impact factor: 4.511

9.  The clinical features and diagnosis of Metachromatic leukodystrophy: A case series of Iranian Pediatric Patients.

Authors:  Sayena Jabbehdari; Elham Rahimian; Narjes Jafari; Sara Sanii; Simin Khayatzadehkakhki; Habibe Nejad Biglari
Journal:  Iran J Child Neurol       Date:  2015

10.  Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy.

Authors:  Jan-Mendelt Tillema; Marloes Gm Derks; Petra J W Pouwels; Pim de Graaf; Diane F van Rappard; Frederik Barkhof; Marjan E Steenweg; Marjo S van der Knaap; Nicole I Wolf
Journal:  Ann Clin Transl Neurol       Date:  2015-08-24       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.